Boston Scientific Corporation (NYSE:BSX) Given Consensus Rating of “Buy” by Analysts

Shares of Boston Scientific Corporation (NYSE:BSX) have been given a consensus rating of “Buy” by the twenty-four research firms that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating, twenty have given a buy rating and two have issued a strong buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $124.85.

Several analysts have recently issued reports on the stock. Barclays upped their target price on shares of Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research report on Thursday, October 2nd. Leerink Partners raised their price objective on Boston Scientific from $127.00 to $128.00 and gave the company an “outperform” rating in a research note on Wednesday, October 1st. Needham & Company LLC reissued a “buy” rating and set a $121.00 target price on shares of Boston Scientific in a research report on Friday, October 17th. Royal Bank Of Canada raised their price target on Boston Scientific from $125.00 to $130.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. Finally, Morgan Stanley lifted their price objective on shares of Boston Scientific from $125.00 to $130.00 and gave the stock an “overweight” rating in a research note on Thursday, October 23rd.

Boston Scientific Stock Down 0.1%

NYSE BSX opened at $96.02 on Monday. The stock has a 50 day moving average price of $98.53 and a 200-day moving average price of $101.09. Boston Scientific has a one year low of $85.98 and a one year high of $109.50. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. The company has a market capitalization of $142.35 billion, a P/E ratio of 51.35, a P/E/G ratio of 1.93 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The company had revenue of $5.07 billion for the quarter, compared to analysts’ expectations of $4.97 billion. During the same quarter in the previous year, the business posted $0.63 earnings per share. Boston Scientific’s quarterly revenue was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. As a group, equities analysts predict that Boston Scientific will post 2.85 EPS for the current fiscal year.

Insider Activity at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $99.47, for a total value of $4,973,500.00. Following the sale, the executive vice president directly owned 178,342 shares of the company’s stock, valued at $17,739,678.74. This represents a 21.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ellen M. Zane sold 12,891 shares of the firm’s stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the sale, the director directly owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. The trade was a 34.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 143,095 shares of company stock worth $14,228,950. Insiders own 0.50% of the company’s stock.

Institutional Trading of Boston Scientific

A number of hedge funds and other institutional investors have recently bought and sold shares of BSX. Steph & Co. bought a new position in shares of Boston Scientific in the third quarter worth about $25,000. Financial Consulate Inc. purchased a new stake in Boston Scientific in the 3rd quarter valued at about $25,000. Murphy & Mullick Capital Management Corp grew its stake in Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 170 shares in the last quarter. 1248 Management LLC purchased a new position in shares of Boston Scientific during the first quarter worth approximately $26,000. Finally, FWL Investment Management LLC bought a new stake in shares of Boston Scientific during the second quarter valued at approximately $26,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.